Singzyme’s mission is to deliver on the promise of effective immuno-therapies by developing safer and more homogenous, precision medicines for the well-being of patients worldwide.
Backed by our first-in-class bioconjugation platform, we support the global pharmaceutical industries with their Research and Development (R&D) endeavours to allow promising therapeutics to reach the patient bedside as fast as possible at the best cost.
The core technology of the platform lies in the use of Peptide Asparaginyl Ligases (PALs) to conjugate active drugs or any other payloads to proteins.
Singzyme's platform for antibodies and nanobodies engineering and conjugation provides a one- stop solution to the problems faced by Antibody Drug Conjugates developers, stemming from their manufacturing process. Singzyme provides an integrated, high-speed, precision bio-manufacturing platform for ADCs and other bioconjugates.